Bio-Path Holdings, Inc. (BPTH)
Largest Insider Buys in Sector
BPTH Stock Price History Chart
BPTH Stock Performance
About Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing …
Insider Activity of Bio-Path Holdings, Inc.
Over the last 12 months, insiders at Bio-Path Holdings, Inc. have bought $0 and sold $0 worth of Bio-Path Holdings, Inc. stock.
On average, over the past 5 years, insiders at Bio-Path Holdings, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,343 shares for transaction amount of $8,958 was made by Garrison Michael J. (director) on 2015‑07‑13.
List of Insider Buy and Sell Transactions, Bio-Path Holdings, Inc.
| 2019-01-18 | Sale | 10 percent owner | 64,457 5.7695% | $2.66 | $171,643 | +381.85% | ||
| 2015-07-13 | director | 7,343 0.0076% | $1.22 | $8,958 | +13.64% | |||
| 2015-07-09 | director | 8,724 0.0097% | $1.17 | $10,207 | +27.35% | |||
| 2015-07-08 | director | 21,015 0.0244% | $1.20 | $25,218 | +29.57% | |||
| 2015-07-07 | director | 38,985 0.0424% | $1.18 | $46,006 | +23.14% | |||
| 2013-06-12 | director | 340,000 0.2889% | $0.30 | $102,000 | +376.42% | |||
| 2009-12-02 | director | 350,000 0.4559% | $0.25 | $87,500 | -11.11% | |||
| 2009-10-13 | director | 400,000 0.6337% | $0.25 | $100,000 | +10.81% |